

## lIatretotide

<b>Cat. No.:</b>	HY-P2229
<b>CAS No.:</b>	119719-11-8
<b>Molecular Formula:</b>	C <sub>61</sub> H <sub>86</sub> N <sub>10</sub> O <sub>20</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	1343.52
<b>Target:</b>	Somatostatin Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

lIatretotide (SDZ CO61), glycosylated somatostatin derivative, is a highly potent glycosylated analog of somatostatin with improved oral activity. lIatretotide can suppress the fasting level and postprandial release of several gastrointestinal and pancreatic hormones. lIatretotide can be used for the research of gastroenteropancreatic tumors<sup>[1][2][3]</sup>.

### REFERENCES

- [1]. Drum, et al. Use of somatostatin analogs in myocardial perfusion imaging. Patent. WO2008143958 A1.
- [2]. Nelson-Piercy C, et al. Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects. J Clin Endocrinol Metab. 1994 Feb;78(2):329-36.
- [3]. Albert R, et al. SDZ CO 611: a highly potent glycosylated analog of somatostatin with improved oral activity. Life Sci. 1993;53(6):517-25.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA